Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 4/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.68 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.63 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5140058 | 1.00 | ADORA2A (0.68) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7730067 | 0.97 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7730071 | 0.97 | ADORA2A (0.70) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7343340 | 0.93 | ADORA2A (0.79) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7343327 | 0.93 | ADORA2A (0.79) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL5141486 | 0.89 | ADORA2A (0.79) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL5141484 | 0.89 | ADORA2A (0.79) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7722549 | 0.86 | ADORA2A (0.72) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL7722552 | 0.86 | ADORA2A (0.72) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 | |
| SCHEMBL12628563 | 0.84 | ADORA2A (0.69) | ADORA2AADORA3ADORA2BHTR1ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023215702-A2 | COMPOSITIONS FOR AND METHODS OF TREATMENT WITH MUTANT A1 ADENOSINE RECEPTOR PLASMID CDNAS | WILSON CONSTANCE (US) | 2023-11-09 | — | — | WO | disclosed |
| US-20230346883-A1 | COMPOSITIONS FOR AND METHODS OF TREATMENT WITH MUTANT A1 ADENOSINE RECEPTOR PLASMID cDNAs | ENDACEA, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20120282284-A1 | METHODS AND COMPOSITIONS FOR PRODUCING ANTIGENIC RESPONSES | WILSON CONSTANCE N (US) | 2012-11-08 | — | — | US | disclosed |
| US-8247231-B2 | Contacting the antigen-presenting cell with an A1 adenosine receptor activating agent in an amount sufficient to increase the antigenic response of the antigen-presenting cell to the antigen; immunology; anticarcinogenic and -tumor agents; prostate cancer; autoimmune diseases; graft versus host disease | ENDACEA, INC. | 2012-08-21 | — | — | US | disclosed |
| US-20050075308-A1 | Methods and compositions for producing antigenic responses | ENDACEA, INC. | 2005-04-07 | — | — | US | disclosed |
| US-6680052-B1 | Methods of inhibiting tumor growth using adenosine receptor activated cells | ENDACEA, INC. | 2004-01-20 | — | — | US | disclosed |
| EP-1043928-A4 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING TUMORS USING ADENOSINE RECEPTOR ACTIVATED CELLS | LINK TECHNOLOGY INC (US) | 2001-01-17 | — | — | EP | disclosed |
| US-6159701-A | Method and compositions for treating and diagnosing tumors using adenosine receptor activated cells | LINK TECHNOLOGY INCORPORATED (US) | 2000-12-12 | — | — | US | disclosed |
| EP-1043928-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING TUMORS USING ADENOSINE RECEPTOR ACTIVATED CELLS | Link Technology, Inc. (US) | 2000-10-18 | — | — | EP | disclosed |
| WO-1998019541-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING TUMORS USING ADENOSINE RECEPTOR ACTIVATED CELLS | LINK TECHNOLOGY, INC. (US) | 1998-05-14 | — | — | WO | disclosed |